Company intelligence / Profile preview
Vycellix
Tampa, Florida, United Statesvycellix.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Vycellix is advancing a suite of proprietary allogeneic and off-the-shelf NK and T-cell immunotherapies. Its lead program, VY‑UC-NK, is an off-the-shelf NK cell product candidate targeting hematological malignancies and is preparing to enter human clinical evaluation. The company’s platforms aim to overcome immune rejection and improve the efficacy, speed, and cost-effectiveness of next-generation cellular immunotherapies. Most programs are in preclinical or early development stages.
- Therapeutic areas
- Oncology
- Modalities
- Allogeneic cell therapiesNatural Killer (NK) cellsT cell therapiesSmall molecules & RNA modulators[4][5]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Avectas (for nonviral gene delivery/cell manufacturing)[5]NextGenNK at Karolinska Institutet (collaborative partner)[1][5]
Beyond the preview
Go deeper on Vycellix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vycellix.